"The antiplatelet effect of aspirin is attributed to platelet cyclooxygenase-1 inhibition. Controversy exists on the prevalence of platelet resistance to aspirin in patients with coronary artery disease and effects of aspirin dose on inhibition. Our primary aim was to determine the degree of platelet aspirin responsiveness in patients, as measured by commonly used methods, and to study the relation of aspirin dose to platelet inhibition."
"Meta-analyses of clinical trials have indicated that aspirin treatment of patients with vascular disease is associated with a 25% to 44% reduction in adverse cardiovascular events. The antithrombotic effect of aspirin has been primarily attributed to the irreversible blockade of the cyclooxygenase-1 (COX-1) enzyme in platelets that leads to attenuation in the production of an important platelet agonist, thromboxane A2. In recent years, an increasing number of reports about aspirin resistance has led to a growing concern among clinicians and patients about the efficacy of aspirin treatment. Various studies have evaluated the antiplatelet effect of aspirin therapy and have reported the prevalence of aspirin resistance to be between 9.4% to 35%."Read More